Tissue-specific Cushing's syndrome, 11beta-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Two isoforms of 11beta-hydroxysteroid dehydrogenase (11beta-HSD) interconvert the active glucocorticoid, cortisol, and inactive cortisone. 11beta-HSD1 acts predominantly as an oxo-reductase in vivo using NADP(H) as a cofactor to generate cortisol. In contrast, 11beta-HSD2 is a NAD-dependent dehydrogenase inactivating cortisol to cortisone, thereby protecting the mineralocorticoid receptor from occupation by cortisol. In peripheral tIssues, both enzymes serve to control the availability of cortisol to bind to corticosteroid receptors. 11beta-HSD2 protects the mineralocorticoid receptor from cortisol excess; mutations in the HSD11B2 gene explain an inherited form of hypertension, the syndrome of 'apparent mineralocorticoid excess', in which 'Cushing's disease of the kidney' results in cortisol-mediated mineralocorticoid excess. Inhibition of 11beta-HSD2 explains the mineralocorticoid excess state seen following liquorice ingestion and more subtle defects in enzyme expression might be involved in the pathogenesis of 'essential' hypertension. 11beta-HSD1 by generating cortisol in an autocrine fashion facilitates glucocorticoid receptor-mediated action in key peripheral tIssues including liver, adipose tissue, bone and the eye. 'Cushing's disease of the omentum' has been proposed as an underlying mechanism in the pathogenesis of central obesity and raises the exciting possibility of selective 11beta-HSD1 inhibition as a novel therapy for patients with the metabolic syndrome. 'Pre-receptor' metabolism of cortisol via 11beta-HSD isozymes is an important facet of corticosteroid hormone action. Aberrant expression of these isozymes is involved in the pathogenesis of diverse human diseases including hypertension, insulin resistance and obesity. Modulation of enzyme activity may offer a future therapeutic approach to treating these diseases whilst circumventing the endocrine consequences of glucocorticoid excess or deficiency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A transgenic model of visceral obesity and the metabolic syndrome
Masuzaki, H., Paterson, J., Shinyama, H., Morton, N. M., Mullins, J. J., Seckl, J. R., & Flier, J. S. (2001) · Science · doi:10.1126/science.1066285 · Cited by 1,766 · cited 1×
“‘Cushing’s disease of the omentum’, mediated via the autocrine expression of 11b-HSD1, may explain the propensity of an individual to develop a central obese phenotype, an hypothesis that is supported through the phenotype of transgenic mice with targeted overexpression of 11b-HSD1 in adipose tissue ( 23 ).”
BackgroundDoes central obesity reflect “Cushing's disease of the omentum”?
Bujalska, I. J., Kumar, S., & Stewart, P. M. (1997) · The Lancet · doi:10.1016/s0140-6736(96)11222-8 · Cited by 753 · cited 2×
“Activity is bi-directional possessing both dehydrogenase (cortisol to cortisone) and reductase (cortisone to cortisol) activity but in vivo in intact cells the enzyme appears to function almost exclusively as a reductase (3, 4 ). As a consequence the enzyme facilitates glucocorticoid receptor (GR)-mediated hormone act…”
BackgroundSelf-citationDraper, N., Walker, E. A., Bujalska, I. J., Tomlinson, J. W., Chalder, S. M., Arlt, W., Lavery, G. G., Bedendo, O., Ray, D. W., Laing, I., et al. (2003) · Nature Genetics · doi:10.1038/ng1214 · Cited by 285
Self-citationUrinary free cortisone and the assessment of 11β‐hydroxysteroid dehydrogenase activity in man
Palermo, M., Shackleton, C. H. L., Mantero, F., & Stewart, P. M. (1996) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1996.00853.x · Cited by 276
Self-citationCooper, M. S., Rabbitt, E. H., Goddard, P. E., Bartlett, W. A., Hewison, M., & Stewart, P. M. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.6.979 · Cited by 200
Self-citation
Cited by
Hermanowski-Vosatka, A., Balkovec, J. M., Cheng, K., Chen, H. Y., Hernandez, M., Koo, G. C., Le Grand, C. B., Li, Z., Metzger, J. M., Mundt, S. S., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050119 · Cited by 364
Adipogenic and lipolytic effects of chronic glucocorticoid exposure
Campbell, J. E., Peckett, A. J., D'souza, A. M., Hawke, T. J., & Riddell, M. C. (2011) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00045.2010 · Cited by 228
Modulation of glucocorticoid metabolism by the growth hormone – IGF‐1 axis
Agha, A., & Monson, J. P. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.02763.x · Cited by 108
Skeletal involvement in adult patients with endogenous hypercortisolism
Chiodini, I., Torlontano, M., Carnevale, V., Trischitta, V., & Scillitani, A. (2008) · Journal of Endocrinological Investigation · doi:10.1007/bf03345601 · Cited by 78
San Millán, J. L., Botella-Carretero, J. I., Álvarez-Blasco, F., Luque-Ramírez, M., Sancho, J., Moghetti, P., & Escobar-Morreale, H. F. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1523 · Cited by 65
Metadata
- Authors
- Stewart, P.
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-09-01
- Volume
- 149
- Issue
- 3
- Pages
- 163-168
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2119610451
- Cited by
- 105
- References
- 5
- FWCI
- 3.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tissue-specific Cushing's syndrome, 11beta-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action. https://app.cochat.ai/papers/10.1530/eje.0.1490163
- The paper
- Stewart, P. (2003). Tissue-specific Cushing's syndrome, 11beta-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action. European Journal of Endocrinology. https://doi.org/10.1530/eje.0.1490163
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.